Skip to content
You are now leaving to visit

Ionis Presents New Data from NEURO-TTR Study and Highlights Programs from Its Neurological Disease Franchise at ANA Congress

Inotersen treatment resulted in a 20-point benefit in mNIS+7 compared to placebo Ionis antisense programs featured in 11 platform and poster presentations at ANA CARLSBAD, Calif. , Oct. 15, 2017 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today